Lunresertib clinical trials
Also written RP-6306.
How each study uses lunresertib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the lunresertib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 2
Debiopharm International SA (3) · University Health Network, Toronto (1) · Canadian Cancer Trials Group (1)
Often tested with
Tested in the same studies.
Niraparib (1) · Camonsertib (1) · CFI-402257 (1) · Ocifisertib fumarate (1) · Sacituzumab govitecan (1)
Studies
Open first, then newest update. How each study uses lunresertib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid TumorsRecruitingPhase 1Debiopharm International SANCT04855656Written as LunresertibHow we know
- Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerRecruitingPhase 2Canadian Cancer Trials GroupNCT05601440Written as RP-6306How we know
- Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine CancerActive, not recruitingPhase 1University Health Network, TorontoNCT06107868Written as RP-6306How we know
- Study of RP-6306 With FOLFIRI in Advanced Solid TumorsTerminatedPhase 1Debiopharm International SANCT05147350Written as RP-6306 (oral PKMYT1 inhibitor)How we know
- Study of RP-6306 With Gemcitabine in Advanced Solid TumorsTerminatedPhase 1Debiopharm International SANCT05147272Written as RP-6306 (oral PKMYT1 inhibitor)How we know
Given beside what is tested · 1 — lunresertib is usual care or a partner of the new treatment
Codes
What other systems call lunresertib · ClinicalTrials.gg INT017368
- UNII (FDA) N95U3A7N57LUNRESERTIBOne source FDA
- NCI Thesaurus C179323LunresertibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | N95U3A7N57 | LUNRESERTIB | One source FDA |
| NCI Thesaurus | C179323 | Lunresertib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.